Covington Firm's Cancer Drug Exceeds Expectations at Enrollment
A Covington-based firm working on a cancer treatment announced Tuesday that part three of its Phase I first-in-human trial exceeded expectations in screening and enrollment at four trial sites.
Bexion Pharmaceuticals is testing BXQ-350 for the treatment of cancer.
In the first few weeks of opening parh three, more than twenty solid tumor patients enrolled with additional patients in screening. The purpose of part three is to explore safety and additional indications in rare and gastrointestinal tumors, the company announced.
The first phase showed that BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy, Bexion stated in a news release. In part two, the highest dose was tested in an additional thirty-six solid tumor patients. Preliminary data support a safe and tolerable drug profile, the company said.
“The safety profile of our drug illustrated in phase one, part one and two of our trial has created enthusiasm about BXQ-350 among our principal investigators,” said Dr. Ray Takigiku, founder and CEO of Bexion. “The objective of part three is to build and expand on the impressive results observed in our prior phase one studies. The rapid enrollment is a reflection of the strong safety profile demonstrated for BXQ-350 and underscores the unmet medical need for new and novel treatment options in these patient populations.”